Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

Hikma Pharmaceuticals (OTCPK:HKMPF) announced on Thursday that it has acquired the FDA-approved Abbreviated New Drug ...

Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it ...

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis ...

Swiss pharmaceutical firm Novartis AG plans to invest $23 billion in the US over the next five years to ensure its key drugs ...

A three-judge panel wrestled Thursday with Novartis AG’s challenge against the FDA over its approval of a generic version of ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

A Swiss drug giant has gotten the message from President Trump’s tariff threats. Novartis said Thursday it will spend $23 ...

Besides, Novartis, Johnson & Johnson plans to spend $55 billion over four years on domestic manufacturing, research and technology. Merck announced plans to spend $1 billion on a vaccine ...